Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 17:2014:348726.
doi: 10.1155/2014/348726. eCollection 2014.

Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety

Nahid A Qushmaq  1 , Samar A Al-Emadi  2
Affiliations
Review

Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety

Nahid A Qushmaq et al. ISRN Rheumatol. .

Abstract

Context. Antiphospholipid antibodies syndrome is an autoimmune disorder that is characterized by the association between presence of antiphospholipid antibodies and risk of thrombosis and/or pregnancy morbidity. Objectives. To systematically review the evidence for primary prophylaxis in patients with antiphospholipids antibodies syndrome or APS with or without other traditional risk factors of thrombosis when they did not have any thrombotic event yet. Methods. PubMed, the Cochrane Library, and Allied Health Literature were searched for studies that examined the efficacy and safety of primary prophylaxis in aPL patients from 1990 to February 2013. We examined literature looking at patients with aPLs with other risk factors for thrombosis and aPLs with no additional risk factors for thrombosis. Conclusion. We concluded that, in patients with aPLs, primary prophylaxes with HCQ and aspirin have been observed to reduce the frequency of thrombotic events in the case of asymptomatic aPL-positive patients with SLE. We also in this study concluded that LDA was effective in patients with autoimmune diseases. Independent cardiovascular risk factors include autoimmune defects such as SLE, rheumatoid arthritis, and atherosclerosis, where overall venous thrombosis will be induced by systemic inflammation. This review concludes that HCQ is an effective primary approach when compared to aspirin.

PubMed Disclaimer

References

    1. Asherson RA, Cervera R, Piette JC, et al. The antiphospholipid syndrome: history, definition, classification, and differential diagnosis. In: Asherton RA, Cervera R, Piette JC, et al., editors. The Antiphospholipid Syndrome. Boca Raton, Fla, USA: CRC Press; 1996. pp. 3–12.
    1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis and Rheumatology. 1999;42(7):1309–1311. - PubMed
    1. Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nature Clinical Practice Rheumatology. 2009;5(3):160–170. - PubMed
    1. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. The New England Journal of Medicine. 2002;346(10):752–763. - PubMed
    1. Bordin G, Boldorini R, Meroni PL. The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus. 2003;12(11):851–853. - PubMed

LinkOut - more resources